Checkpoint Therapeutics price target raised to $7 from $4 at Lake Street

Lake Street analyst Thomas Flaten raised the firm’s price target on Checkpoint Therapeutics (CKPT) to $7 from $4 and keeps a Buy rating on the shares after the company announced FDA approval of Unloxcyt for advanced cutaneous squamous cell carcinoma on Friday. The firm expects commercialization, likely in the second half of 2025, will be “via acquisition/partnership,” the analyst tells investors.